Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 9/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 9/20 | 0.54 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1080624 | 0.99 | CYP4F2 (0.53) | CYP4F2CYP4A11WNT3ACYP2D6HRH3 | |
| SCHEMBL980281 | 0.86 | TDP1 (0.48) | CYP4F2CYP4A11CYP2D6HRH3TDP1 | |
| SCHEMBL1078144 | 0.85 | CYP4F2 (0.52) | CYP4F2CYP4A11WNT3AGPR119 | |
| SCHEMBL982179 | 0.84 | CYP4F2 (0.50) | CYP4F2CYP4A11WNT3AGPR119GPR183 | |
| SCHEMBL1092945 | 0.83 | GPR119 (0.53) | CYP4F2CYP4A11WNT3AGPR119GPR183 | |
| SCHEMBL978339 | 0.83 | CYP4F2 (0.49) | CYP4F2CYP4A11WNT3AGPR119GPR183 | |
| SCHEMBL978046 | 0.83 | CYP4F2 (0.49) | CYP4F2CYP4A11WNT3AGPR119 | |
| SCHEMBL979073 | 0.82 | GPR119 (0.59) | CYP4F2CYP4A11GPR119 | |
| SCHEMBL9947664 | 0.82 | CYP4F2 (0.48) | CYP4F2CYP4A11WNT3AGPR119GPR183 | |
| SCHEMBL981851 | 0.80 | GPR119 (0.60) | CYP4F2CYP4A11WNT3AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207344-B2 | GPR119 agonists | ELI LILLY AND COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2454251-A1 | GPR119 AGONISTS | Eli Lilly and Company (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008663-A1 | GPR119 AGONISTS | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015199-A1 | GPR119 Agonists | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015199-A1 | GPR119 Agonists | GPR119, GLP1R, GCGR | CYP4F2 1001/4885CYP4A11 510/4885WNT3A 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.